surmount-1 tirzepatide weight loss percent nejm 2022 for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial 📊 Semaglutide 2.4mg: −13.7% weight

This dual action was shown in clinical trials to produce greater weight reduction than single-pathway medications like semaglutide alone

Tirzepatide does not directly cause frequent urination as a primary pharmacological effect

For instance, if a person has a co-occurring mental health disorder like depression or ADHD, medications and support may be targeted to treat these concerns as well

This dual action contributes to effective glycemic control and weight loss

How to maximize safety and results To maximize safety and achieve the best possible outcomes with sermorelin, a proactive and collaborative approach with your healthcare provider is essential